PT109
PT109 is a multi-kinase inhibitor. PT109 inhibits JNK (JNK1: IC50=0.143 μM; JNK2: IC50=0.831 μM; JNK3: IC50=0.285 μM) and other kinases (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM; ROCK2: IC50=34 μM) and plays an important role in anti-inflammation, anti-oxidation, neurogenesis, synaptogenesis, etc. In addition, PT109 also reprograms glioblastoma multiforme (GBM) into oligodendrocytes through the PTBP1/PKM1/2 pathway and changes the metabolic pattern of GBM, exerting anti-glioma activity[1][2].
Product Specifications
CAS Number
2059104-90-2
UNSPSC
12352005
Target
JNK; ROCK; SGK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Cytoskeleton; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Stem Cell/Wnt; TGF-beta/Smad
Applications
COVID-19-anti-virus
Field of Research
Cancer; Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/pt109.html
Purity
99.20
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(CCCCC1SSCC1)NC2CCC(CC2)NC3=CC=CC4=C3C=CN=C4
Molecular Formula
C23H31N3OS2
Molecular Weight
429.64
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JNK1; JNK2; JNK3; ROCK2; SGK1; SGK3
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Lentiviral human RANBP17 shRNA (UAS) - Lentiviral human RANBP17 shRNA (UAS, iRFP) plasmid
Recombinant Leuconostoc mesenteroides Bacteriocin mesentericin Y105 (mesY)
Recombinant Leuconostoc mesenteroides Bacteriocin mesentericin Y105 (mesY)
Recombinant Leuconostoc mesenteroides Bacteriocin mesentericin Y105 (mesY)